Biomarin Pharmaceutical IncBMRN
Price$58.44Intrinsic value$101.0973% above price

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $3.4B+19.4% YoYTTM through 30 Jun 2026
Net Income $73M-82.9% YoYTTM through 30 Jun 2026
Free Cash Flow $738.2MTTM through 30 Jun 2026

Margins

Current
Gross Margin74.6%
EBITDA Margin8.9%
Operating Margin16.9%
Net Margin2.1%

Returns

4.3%ROE
3.1%ROA
0.8%ROIC

Balance Sheet Health

Debt / Equity0.23x
Current Ratio5.81x
Net Debt-$792.2Mnet cash position
Cash & Equivalents$874M

Quality Metrics

Altman Z-Score1.97
Piotroski F-Score4 / 9
FCF Margin21.7%
Rule of 4036.3
Earnings-Beat Rate25.0%

Multi-Year Trend

Revenue
'19'20'21'22'23'24'25
FY2025: $3.2B
Diluted EPS$0.38TTM
'19'20'21'22'23'24'25
FY2025: $1.80

Dividend

No dividend

Capital Allocation

R&D Spend$987.6M
Capex Intensity3.5%
All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.